U.S. market Closed. Opens in 3 hours 25 minutes

IMVT | Immunovant, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-31
RevenueN/AN/AN/AN/AN/AN/AN/A
Cost of Revenue231.00K1.32M1.23M998.00K21.00KN/AN/A
Gross Profit-231.00K-1.32M-1.23M-998.00K-21.00KN/AN/A
Operating Expenses282.71M208.28M156.03M108.12M66.08M448.00136.74M
Selling, General & Admin57.28M48.02M54.23M39.51M18.15M448.001.48M
Research & Development212.93M160.26M101.81M68.60M47.93M25.73M135.26M
Other Operating Expenses12.50M-253.00K-781.00K328.00K412.00KN/AN/A
Operating Income-282.71M-198.47M-156.16M-107.79M-65.67M-450.00-136.74M
Other Expenses / Income23.94M-2.67M-781.00K328.00K-2.51MN/A116.00
Before Tax Income-258.77M-210.95M-156.81M-107.79M-66.29M-448.00-136.74M
Income Tax Expenses567.00K9.00K-84.00K-358.00K97.00K19.00KN/A
Net Income-259.34M-210.96M-156.73M-107.43M-66.39M-448.00-136.74M
Interest ExpensesN/A12.48M655.00KN/A625.00KN/AN/A
Basic Shares Outstanding138.10M123.08M109.68M87.76M43.20M14.38M10.00M
Diluted Shares Outstanding138.10M123.08M109.68M87.76M43.20M14.38M10.00M
EBITDA-269.98M-209.63M-155.58M-106.79M-65.64M-28.41MN/A
EBITDA Margin0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIT-258.77M-198.47M-156.16M-107.79M-65.67M18.55K-136.74M
EBIT Margin0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Financial Year End2024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙